Age-related risk of adverse events following yellow fever vaccination in Australia
DOI:
https://doi.org/10.33321/cdi.2004.28.24Keywords:
vaccination, yellow feverAbstract
Reports of six deaths internationally, including one from Australia, plus other cases of severe systemic adverse events following yellow fever (YF) vaccination have raised concern about the safety of YF vaccine, particularly among older vaccinees. We investigated the age-related reporting rates of adverse events following YF vaccination reported to the Australian Adverse Drug Reactions Advisory Committee for the period 1993 to 2002. The reporting rate of systemic adverse events leading to hospitalisation or death was significantly higher among vaccinees aged ≥65 years reporting rate ratio (RRR) 8.95, 95% confidence interval (CI) 1.49-53.5 or ≥45 years (RRR 5.30, 95% CI 1.33-21.2) compared with younger YF vaccinees. The higher reporting rates among older vaccinees are similar to those identified in the United States of America. The data highlight the importance of assessing the destination-specific risk, especially for older travellers to yellow fever endemic areas, and careful monitoring of those who are vaccinated. Commun Dis Intell 2004;28:244-248.
Downloads
References
Marianneau P, Georges-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow fever vaccination.
Mortimer PP. Yellow fever vaccine. [Editorial] BMJ 2002;324:439.
Cetron MS, Marfin AA, Julian KG, Gubler DJ, Barwick RS, et al. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002;51:1-11.
Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002;51:989-993.
Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001;7:945-951.
Martin M, Tsai TF, Cropp B, Chang G-J, Holmes DA, Tseng J, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001;358:98-104.
Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001;358:91-97.
Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001;358:121-122.
Adhiyaman V, Oke A, Cefai C. Effects of yellow fever vaccination. Lancet 2001;358:1907-1908.
Troillet N, Laurencet F. Effects of yellow fever vaccination. Lancet 2001;358:1908-1909.
Werfel U, Popp W. Effects of yellow fever vaccination. Lancet 2001;358:1909.
Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Surveillance of adverse events following immunisation: Australia 2000-2002. Commun Dis Intell 2003;27:307-323.
Dean AG, Dean JA, Coulombier D, et al. Epi Info version 6: a word processing, database and statistics program for epidemiology on microcomputers. Atlanta, Georgia, USA: Centers for Disease Control and Prevention, 1994.
National Health and Medical Research Council. The Australian Immunisation Handbook. 8th edition. Canberra: Australian Government Publishing Service; 2003. p. 292-294. Available from: http://immunise.health.gov.au/handbook.htm
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2004 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
